1
|
Surace T, Buoli M, Affaticati LM, Esposito G, Capuzzi E, Colzani L, La Tegola D, Biagi E, Colmegna F, Caldiroli A, Clerici M. Which clinical factors delay proper treatment in panic disorder? A cross-sectional multicentric study. Early Interv Psychiatry 2024. [PMID: 38357849 DOI: 10.1111/eip.13506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 11/30/2023] [Accepted: 01/24/2024] [Indexed: 02/16/2024]
Abstract
AIM The aim of the present study was to identify clinical and socio-demographic factors associated with duration of untreated illness (DUI) in patients affected by panic disorder (PD). METHODS Data were collected from patients' medical records (N = 157) of two mental health services respectively located in Milan and in Monza (Italy). Correlation analyses and analysis of variance (ANOVAs) were run to analyse the relation between DUI and quantitative/qualitative variables respectively. Statistically significant variables in uni- variate analyses were then inserted in a linear multivariable regression model (backward procedure). RESULTS Mean DUI was 27.33 (±50.56) months. Patients with an earlier age at onset (r = -0.270; p < .01), a longer duration of illness (r = 0.483; p < .01) and who received a lifetime psychotherapy (F = 6.86; p = .01) had a longer DUI. The final global model showed that a longer DUI was associated with pre-onset poly-substance misuse (p = .05) and a longer duration of illness (p < .01). CONCLUSION The results of our study showed that a longer DUI was predicted by clinical factors such as the presence of a pre-onset poly-substance use disorder and that delayed proper treatment can lead to a chronicization of PD, as indicated by a longer duration of illness. Further studies are needed to in-depth investigate the role of DUI in influencing the course and outcome of anxiety disorders, including PD.
Collapse
Affiliation(s)
- T Surace
- Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - M Buoli
- Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - L M Affaticati
- Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
| | - G Esposito
- Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
| | - E Capuzzi
- Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - L Colzani
- Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
| | - D La Tegola
- Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - E Biagi
- Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - F Colmegna
- Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - A Caldiroli
- Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - M Clerici
- Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
- Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
| |
Collapse
|
2
|
Quercia S, Freccero F, Castagnetti C, Soverini M, Turroni S, Biagi E, Rampelli S, Lanci A, Mariella J, Chinellato E, Brigidi P, Candela M. Early colonisation and temporal dynamics of the gut microbial ecosystem in Standardbred foals. Equine Vet J 2018; 51:231-237. [PMID: 29931762 DOI: 10.1111/evj.12983] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 06/19/2018] [Indexed: 12/11/2022]
Abstract
BACKGROUND Even if horses strictly depend on the gut microbiota for energy homeostasis, only a few molecular studies have focused on its characterisation and none on the perinatal gut microbial colonisation process. OBJECTIVES To explore the perinatal colonisation process of the foal gut microbial ecosystem and the temporal dynamics of the ecosystem assembly during the first days of life. STUDY DESIGN Longitudinal study. METHODS Thirteen Standardbred mare-foal pairs were included in the study. For each pair, at delivery we collected the mare amniotic fluid, faeces and colostrum, and the foal meconium. Milk samples and faeces of both mare and foal were also taken longitudinally, until day 10 post-partum. Samples were analysed by means of next-generation sequencing of the 16S rRNA gene on Illumina MiSeq. RESULTS Our findings suggest that microbial components derived from the mare symbiont communities establishes in the foal gut since fetal life. After birth, an external transmission route of mare microorganisms takes place. This involves a rapid and dynamic process of assembling the mature foal gut microbiome, in which the founder microbial species are derived from both the milk and the gut microbial ecosystems of the mare. MAIN LIMITATIONS The inability to discriminate between live and dead cells, the possible presence of contaminating bacteria in low biomass samples (e.g. meconium and amniotic fluid), the limits of the phylogenetic assignment down to species level, and the presence of unassigned operational taxonomic units. CONCLUSIONS Our data highlight the importance of mare microbiomes as a key factor for the establishment of the gut microbial ecosystem of the foal.
Collapse
Affiliation(s)
- S Quercia
- Unit of Microbial Ecology of Health, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - F Freccero
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - C Castagnetti
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - M Soverini
- Unit of Microbial Ecology of Health, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - S Turroni
- Unit of Microbial Ecology of Health, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - E Biagi
- Unit of Microbial Ecology of Health, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - S Rampelli
- Unit of Microbial Ecology of Health, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - A Lanci
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - J Mariella
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - E Chinellato
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - P Brigidi
- Unit of Microbial Ecology of Health, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - M Candela
- Unit of Microbial Ecology of Health, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| |
Collapse
|
3
|
Magnani C, Mezzanotte C, Cappuzzello C, Benedicenti F, Belotti D, Cabiati B, Bardini M, Fazio G, Cazzaniga G, Cooper L, Montini E, Gaipa G, Biondi A, Biagi E. Preclinical evaluation of donor-derived sleeping beauty modified CD19CAR+ lymphocytes for the treatment of acute lymphoblastic leukemia. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia 2017; 31:1087-1095. [PMID: 28126984 DOI: 10.1038/leu.2017.39] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Revised: 11/21/2016] [Accepted: 01/05/2017] [Indexed: 12/23/2022]
Abstract
Trials with second generation CD19 chimeric antigen receptors (CAR) T-cells report unprecedented responses but are associated with risk of cytokine release syndrome (CRS). Instead, we studied the use of donor Epstein-Barr virus-specific T-cells (EBV CTL) transduced with a first generation CD19CAR, relying on the endogenous T-cell receptor for proliferation. We conducted a multi-center phase I/II study of donor CD19CAR transduced EBV CTL in pediatric acute lymphoblastic leukaemia (ALL). Patients were eligible pre-emptively if they developed molecular relapse (>5 × 10-4) post first stem cell transplant (SCT), or prophylactically post second SCT. An initial cohort showed poor expansion/persistence. We therefore investigated EBV-directed vaccination to enhance expansion/persistence. Eleven patients were treated. No CRS, neurotoxicity or graft versus host disease (GVHD) was observed. At 1 month, 5 patients were in CR (4 continuing, 1 de novo), 1 PR, 3 had stable disease and 3 no response. At a median follow-up of 12 months, 10 of 11 have relapsed, 2 are alive with disease and 1 alive in CR 3 years. Although CD19CAR CTL expansion was poor, persistence was enhanced by vaccination. Median persistence was 0 (range: 0-28) days without vaccination compared to 56 (range: 0-221) days with vaccination (P=0.06). This study demonstrates the feasibility of multi-center studies of CAR T cell therapy and the potential for enhancing persistence with vaccination.
Collapse
MESH Headings
- Antigens, CD19
- Child
- Child, Preschool
- Chimera
- Female
- Herpesvirus 4, Human
- Humans
- Immunotherapy/methods
- Immunotherapy, Adoptive
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Receptors, Antigen, T-Cell/genetics
- Receptors, Antigen, T-Cell/immunology
- Recurrence
- T-Lymphocytes, Cytotoxic/transplantation
- T-Lymphocytes, Cytotoxic/virology
- Vaccination
Collapse
Affiliation(s)
- C Rossig
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - M Pule
- Department of Haematology, Cancer Institute, University College London, London, UK
| | - B Altvater
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - S Saiagh
- Unite de Therapie Cellulaire et Genetique, CHU Nantes, Nantes, France
| | - G Wright
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
| | - S Ghorashian
- Molecular and Cellular Immunology Section, Institute of Child Health, University College London, London, UK
| | | | - K Champion
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - Z Sattar
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - B Popova
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - A Hackshaw
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - P Smith
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - T Roberts
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - E Biagi
- Clinica Pediatrica, Università Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza, Italy
| | - B Dreno
- Unite de Therapie Cellulaire et Genetique, CHU Nantes, Nantes, France
| | - R Rousseau
- Department of Pediatric Haemato-Oncology, Centre Leon Berard, Lyon, France
| | - S Kailayangiri
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - M Ahlmann
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - R Hough
- Department of Haematology, Cancer Institute, University College London, London, UK
| | - B Kremens
- Department of Pediatric Hematology and Oncology, University Children's Hospital Essen, Essen, Germany
| | - M G Sauer
- Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
| | - P Veys
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
| | - N Goulden
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
| | - M Cummins
- Department of Bone Marrow Transplant, Bristol Royal Hospital for Children, Bristol, UK
| | - P J Amrolia
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
- Molecular and Cellular Immunology Section, Institute of Child Health, University College London, London, UK
| |
Collapse
|
5
|
Arcangeli S, Rotiroti M, Bardelli M, Simonelli L, Magnani C, Varani L, Biondi A, Tettamanti S, Biagi E. Balance of anti-CD123 Chimeric Antigen Receptor (CAR) binding affinity and density for the targeting of Acute Myeloid Leukemia. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
6
|
Vannacci E, Granchi S, Belsito L, Roncaglia A, Biagi E. Wide bandwidth fiber-optic ultrasound probe in MOMS technology: Preliminary signal processing results. Ultrasonics 2017; 75:164-173. [PMID: 27992840 DOI: 10.1016/j.ultras.2016.11.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 09/29/2016] [Accepted: 11/29/2016] [Indexed: 06/06/2023]
Abstract
An ultrasonic probe consisting of two optical fiber-based miniaturized transducers for wideband ultrasound emission and detection is employed for the characterization of in vitro biological tissues. In the probe, ultrasound generation is obtained by thermoelastic emission from patterned carbon films in Micro-Opto-Mechanical-System (MOMS) devices mounted on the tip of an optical fiber, whereas acousto-optical detection is performed in a similar way by a miniaturized polymeric interferometer. The microprobe presents a wide, flat bandwidth that is a very attractive feature for ultrasonic investigation, especially for tissue characterization. Thanks to the very high ultrasonic frequencies obtained, the probe is able to reveal different details of the object under investigation by analyzing the ultrasonic signal within different frequencies ranges, as shown by specific experiments performed on a patterned cornstarch flour sample in vitro. This is confirmed by measurements executed to determine the lateral resolution of the microprobe at different frequencies of about 70μm at 120MHz. Moreover, measurements performed with the wideband probe in pulsed-echo mode on a histological finding of porcine kidney are presented, on which two different spectral signal processing algorithms are applied. After processing, the ultrasonic spectral features show a peculiar spatial distribution on the sample, which is expected to depend on different ultrasonic backscattering properties of the analyzed tissues.
Collapse
Affiliation(s)
- E Vannacci
- Department of Information Engineering (DINFO), University of Florence, Via Santa Marta 3, 50139 Florence, Italy.
| | - S Granchi
- Department of Information Engineering (DINFO), University of Florence, Via Santa Marta 3, 50139 Florence, Italy
| | - L Belsito
- Institute of Microelectronics and Microsystems (IMM), National Research Council (CNR), Via Piero Gobetti, 101, 40129 Bologna, Italy
| | - A Roncaglia
- Institute of Microelectronics and Microsystems (IMM), National Research Council (CNR), Via Piero Gobetti, 101, 40129 Bologna, Italy
| | - E Biagi
- Department of Information Engineering (DINFO), University of Florence, Via Santa Marta 3, 50139 Florence, Italy
| |
Collapse
|
7
|
Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, Turroni S, Centanni M, Severgnini M, Peano C, de Bellis G, Basaglia G, Gotti R, Masetti R, Pession A, Brigidi P, Candela M. Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT. Bone Marrow Transplant 2015; 50:992-8. [PMID: 25893458 DOI: 10.1038/bmt.2015.16] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Revised: 01/19/2015] [Accepted: 01/20/2015] [Indexed: 12/27/2022]
Abstract
Acute GvHD (aGvHD) is the main complication of hematopoietic SCT (HSCT) during the treatment of hematological disorders. We carried out the first longitudinal study to follow the gut microbiota trajectory, from both the phylogenetic and functional points of view, in pediatric patients undergoing HSCT. Gut microbiota trajectories and short-chain fatty acid production profiles were followed starting from before HSCT and through the 3-4 months after transplant in children developing and not developing aGvHD. According to our findings, HSCT procedures temporarily cause a structural and functional disruption of the gut microbial ecosystem, describing a trajectory of recovery during the following 100 days. The onset of aGvHD is associated with specific gut microbiota signatures both along the course of gut microbiota reconstruction immediately after transplant and, most interestingly, prior to HSCT. Indeed, in pre-HSCT samples, non-aGvHD patients showed higher abundances of propionate-producing Bacteroidetes, highly adaptable microbiome mutualists that showed to persist during the HSCT-induced ecosystem disruption. Our data indicate that structure and temporal dynamics of the gut microbial ecosystem can be a relevant factor for the success of HSCT and opens the perspective to the manipulation of the pre-HSCT gut microbiota configuration to favor mutualistic persisters with immunomodulatory properties in the gut.
Collapse
Affiliation(s)
- E Biagi
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - D Zama
- Pediatric Oncology and Haematology Unit "Lalla Seràgnoli", Department of Pediatrics, University of Bologna, Sant'Orsola Malpighi Hospital, Bologna, Italy
| | - C Nastasi
- Pediatric Oncology and Haematology Unit "Lalla Seràgnoli", Department of Pediatrics, University of Bologna, Sant'Orsola Malpighi Hospital, Bologna, Italy
| | - C Consolandi
- Institute of Biomedical Technologies, Italian National Research Council, Milan, Italy
| | - J Fiori
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - S Rampelli
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - S Turroni
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - M Centanni
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - M Severgnini
- Institute of Biomedical Technologies, Italian National Research Council, Milan, Italy
| | - C Peano
- Institute of Biomedical Technologies, Italian National Research Council, Milan, Italy
| | - G de Bellis
- Institute of Biomedical Technologies, Italian National Research Council, Milan, Italy
| | - G Basaglia
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - R Gotti
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - R Masetti
- Pediatric Oncology and Haematology Unit "Lalla Seràgnoli", Department of Pediatrics, University of Bologna, Sant'Orsola Malpighi Hospital, Bologna, Italy
| | - A Pession
- Pediatric Oncology and Haematology Unit "Lalla Seràgnoli", Department of Pediatrics, University of Bologna, Sant'Orsola Malpighi Hospital, Bologna, Italy
| | - P Brigidi
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - M Candela
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| |
Collapse
|
8
|
Rambaldi A, Biagi E, Bonini C, Biondi A, Introna M. Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014; 29:1-10. [PMID: 24919807 DOI: 10.1038/leu.2014.189] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2014] [Revised: 05/15/2014] [Accepted: 05/27/2014] [Indexed: 12/19/2022]
Abstract
When treatment fails, the clinical outcome of acute leukemia patients is usually very poor, particularly when failure occurs after transplantation. A second allogeneic stem cell transplant could be envisaged as an effective and feasible salvage option in younger patients having a late relapse and an available donor. Unmanipulated or minimally manipulated donor T cells may also be effective in a minority of patients but the main limit remains the induction of severe graft-versus-host disease. This clinical complication has brought about a huge research effort that led to the development of leukemia-specific T-cell therapy aiming at the direct recognition of leukemia-specific rather than minor histocompatibility antigens. Despite a great scientific interest, the clinical feasibility of such an approach has proven to be quite problematic. To overcome this limitation, more research has moved toward the choice of targeting commonly expressed hematopoietic specific antigens by the genetic modification of unselected T cells. The best example of this is represented by the anti-CD19 chimeric antigen receptor (CD19.CAR) T cells. As a possible alternative to the genetic manipulation of unselected T cells, specific T-cell subpopulations with in vivo favorable homing and long-term survival properties have been genetically modified by CAR molecules. Finally, the use of naturally cytotoxic effector cells such as natural killer and cytokine-induced killer cells has been proposed in several clinical trials. The clinical development of these latter cells could also be further expanded by additional genetic modifications using the CAR technology.
Collapse
Affiliation(s)
- A Rambaldi
- Hematology and Bone Marrow Transplant Unit and Center of Cell Therapy 'G. Lanzani', Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - E Biagi
- Department of Pediatrics, M Tettamanti Research Center, Laboratory of Cell therapy 'S. Verri' University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - C Bonini
- Experimental Hematology Unit, San Raffaele Scientific Institute, Milano, Italy
| | - A Biondi
- Department of Pediatrics, M Tettamanti Research Center, Laboratory of Cell therapy 'S. Verri' University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - M Introna
- Hematology and Bone Marrow Transplant Unit and Center of Cell Therapy 'G. Lanzani', Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
9
|
Magnani C, Turazzi N, Benedicenti F, Tettamanti S, Attianese GG, Rossi V, Montini E, Cooper L, Aiuti A, Biondi A, Biagi E. Cytokine-induced killer (CIK) cells engineered with chimeric antigen receptors (CARs) by sleeping beauty system. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Bertilaccio M, Tettamanti S, Attianese GG, Galletti G, Arcangeli S, Rodriguez T, Magnani C, Barbaglio F, Scarfò L, Ponzoni M, Biondi A, Caligaris-Cappio F, Ghia P, Biagi E. Combining CD23 chimeric antigen receptor immunotherapy and lenalidomide as a novel therapeutic strategy for chronic lymphocytic leukemia. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E, Bonnet D. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014; 28:1596-605. [PMID: 24504024 DOI: 10.1038/leu.2014.62] [Citation(s) in RCA: 209] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Revised: 01/28/2014] [Accepted: 01/31/2014] [Indexed: 12/18/2022]
Abstract
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to conventional therapies or experience relapse, immunotherapy using T cells expressing chimeric antigen receptors (CARs) might represent a valid treatment option. AML cells frequently overexpress the myeloid antigens CD33 and CD123, for which specific CARs can be generated. However, CD33 is also expressed on normal hematopoietic stem/progenitor cells (HSPCs), and its targeting could potentially impair normal hematopoiesis. In contrast, CD123 is widely expressed by AML, while low expression is detected on HSPCs, making it a much more attractive target. In this study we describe the in vivo efficacy and safety of using cytokine-induced killer (CIK) cells genetically modified to express anti-CD33 or anti-CD123 CAR to target AML. We show that both these modified T cells are very efficient in reducing leukemia burden in vivo, but only the anti-CD123 CAR has limited killing on normal HSPCs, thus making it a very attractive immunotherapeutic tool for AML treatment.
Collapse
Affiliation(s)
- I Pizzitola
- 1] Department of Pediatrics, Centro di Ricerca 'Matilde Tettamanti', University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy [2] Haematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, UK
| | - F Anjos-Afonso
- Haematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, UK
| | - K Rouault-Pierre
- Haematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, UK
| | - F Lassailly
- Haematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, UK
| | - S Tettamanti
- Department of Pediatrics, Centro di Ricerca 'Matilde Tettamanti', University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - O Spinelli
- Department of Haematology, Ospedale Riuniti, Bergamo, Italy
| | - A Biondi
- Department of Pediatrics, Centro di Ricerca 'Matilde Tettamanti', University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - E Biagi
- Department of Pediatrics, Centro di Ricerca 'Matilde Tettamanti', University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy
| | - D Bonnet
- Haematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, UK
| |
Collapse
|
12
|
Tettamanti S, Marin V, Pizzitola I, Magnani C, Giordano Attianese G, Cribioli E, Maltese F, Lopez A, Biondi A, Bonnet D, Biagi E. Targeting of acute myeloid leukemia (AML) by cytokine-induced killer (CIK) cells redirected with a novel CD123-specific chimeric antigen receptor (CAR). Cytotherapy 2013. [DOI: 10.1016/j.jcyt.2013.01.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
13
|
Rampelli S, Candela M, Severgnini M, Biagi E, Turroni S, Roselli M, Carnevali P, Donini L, Brigidi P. A probiotics-containing biscuit modulates the intestinal microbiota in the elderly. J Nutr Health Aging 2013; 17:166-72. [PMID: 23364497 DOI: 10.1007/s12603-012-0372-x] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
OBJECTIVES Evaluation of the impact of a biscuit containing the probiotics Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 on the intestinal microbiota in the elderly. DESIGN Randomized double-blind placebo-controlled trial. PARTICIPANTS Thirty-two elderly volunteers living in Italy. The group was composed of 19 women and 13 men aged between 71 and 88 years (mean 76). INTERVENTION Subjects were randomized in two groups consuming one dose of the probiotics-containing biscuit or placebo once a day for 30 days. MEASUREMENTS For each subject the intestinal microbiota was characterized using the phylogenetic microarray platform HTF-Microbi.Array before and after intervention. RESULTS Our data demonstrated that one-month consumption of a probiotics-containing biscuit was effective in redressing some of the age-related dysbioses of the intestinal microbiota. In particular, the probiotic treatment reverted the age-related increase of the opportunistic pathogens Clostridium cluster XI, Clostridium difficile, Clostridium perfringens, Enterococcus faecium and the enteropathogenic genus Campylobacter. CONCLUSION The present study opens the way to the development of elderly-tailored probiotic-based functional foods to counteract the age-related dysbioses of the intestinal microbiota.
Collapse
Affiliation(s)
- S Rampelli
- Department of Pharmaceutical Sciences, University of Bologna, Bologna, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Carini F, Menchini Fabris G, Biagi E, Salvade' A, Sbordone L, Baldoni M. Estudio experimental sobre la utilización de células madre humanas en la terapia de los defectos periodontales: resultados preliminares. ACTA ACUST UNITED AC 2011. [DOI: 10.4321/s1699-65852011000200003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
15
|
Lapi S, Calzolai M, Fontana G, Biagi E, Borgioli G, Masotti L. Monitoring of Cardiorespiratory Rates and Respiratory Expulsive Efforts by an Accelerometer in Awake and Sleeping Humans. Pulm Pharmacol Ther 2011. [DOI: 10.1016/j.pupt.2011.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Dander E, Lucchini G, Vinci P, Introna M, Bonanomi S, Balduzzi A, Gaipa G, Perseghin P, Masciocchi F, Capelli C, Golay J, Algarotti A, Rambaldi A, Rovelli A, Biondi A, Biagi E, D'Amico G. Immunomonitoring of Transplanted Patients Infused With Mesenchymal Stromal Cells (MSC) for Treating Steroid-Refractory GVHD. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Lucchini G, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Belotti D, Gaipa G, Perseghin P, Capelli C, Introna M, Rambaldi A, Biondi A, d'Amico G, Biagi E. Platelet-Lysate-Expanded Mesenchymal Stromal Cells for the Treatment of Resistant GVHD. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Balduzzi A, Lucchini G, Hirsch HH, Basso S, Cioni M, Rovelli A, Zincone A, Grimaldi M, Corti P, Bonanomi S, Biondi A, Locatelli F, Biagi E, Comoli P. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2010; 46:987-92. [PMID: 20921942 DOI: 10.1038/bmt.2010.221] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCV-specific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients.
Collapse
Affiliation(s)
- A Balduzzi
- Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, Monza, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Lucchini G, Masera N, Foti G, Assali G, Perseghin P, Biagi E. A life-threatening paediatric case of acute autoimmune haemolytic anaemia (AIHA) successfully cured by plasma-exchange and combined immunosuppressive treatment. Transfus Apher Sci 2009; 40:115-8. [DOI: 10.1016/j.transci.2009.01.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Pastorelli A, Torricelli G, Scabia M, Biagi E, Masotti L. A real-time 2-D vector Doppler system for clinical experimentation. IEEE Trans Med Imaging 2008; 27:1515-1524. [PMID: 18815103 DOI: 10.1109/tmi.2008.927337] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A real-time hardware software 2-D vector Doppler system has been realized by means of the FEMMINA platform. The system operates by performing two independent 1-D Doppler estimations on the scan plane of a linear array probe along different directions; the probe is connected to a commercial scanner. The reconstructed velocity is presented in real-time as superposition on the conventional B-mode images. Two different scanning techniques have been implemented, in order to carry out the 2-D Doppler investigation in the area of interest. These techniques allow to use the system both in vivo and in vivo. An extensive set of simulations has been performed in order to establish a gold standard regarding vector Doppler 2-D techniques, and to be able to assess the performance of the 2-D Doppler system by comparing simulated and experimental results. The whole real-time 2-D vector Doppler system is fully certified as hospital equipment, and thus it can be employed to carry out an experimental characterization of the 2-D Doppler technique in the clinical environment.
Collapse
Affiliation(s)
- A Pastorelli
- Electronics and Telecommunication Department, University of Florence, 50139 Florence, Italy.
| | | | | | | | | |
Collapse
|
21
|
Biagi E, Vitali B, Pugliese C, Candela M, Donders GGG, Brigidi P. Quantitative variations in the vaginal bacterial population associated with asymptomatic infections: a real-time polymerase chain reaction study. Eur J Clin Microbiol Infect Dis 2008; 28:281-5. [PMID: 18762999 DOI: 10.1007/s10096-008-0617-0] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2008] [Accepted: 07/30/2008] [Indexed: 10/21/2022]
Abstract
The real-time polymerase chain reaction (PCR) quantification of several vaginal bacterial groups in healthy women and patients developing asymptomatic bacterial vaginosis (BV) and candidiasis (CA) was performed. Statistical analysis revealed that the BV condition is characterised by a great variability among subjects and that it is associated with a significant increase of Prevotella, Atopobium, Veillonella and Gardnerella vaginalis, and a drop in Lactobacillus. On the contrary, the vaginal microflora of healthy women and patients developing CA was found to be homogeneous and stable over time.
Collapse
Affiliation(s)
- E Biagi
- Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | | | | | | | | | | |
Collapse
|
22
|
Salvadè A, Belotti D, Donzelli E, D'Amico G, Gaipa G, Renoldi G, Carini F, Baldoni M, Pogliani EM, Tredici G, Biondi A, Biagi E. GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease. Cytotherapy 2007; 9:427-38. [PMID: 17786604 DOI: 10.1080/14653240701341995] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Periodontal disease is a degenerative illness that leads to resorption of the alveolar bone. Mesenchymal stromal cells (MSC) represent a novel tool for the production of biologic constructs for the treatment of degenerative bone diseases. The preparation of MSC differentiated into osteogenic lineage for clinical use requires the fulfillment of strict good manufacturing practice (GMP) procedures. METHODS MSC were isolated from BM samples and then cultured under GMP conditions. MSC were characterized phenotypically and for their differentiative potential. Cells were seeded onto collagen scaffolds (Gingistat) and induced to differentiate into osteogenic lineages using clinical grade drugs compared with standard osteogenic supplements. Alizarin Red S stain was used to test the deposition of the mineral matrix. Standard microbiologic analysis was performed to verify the product sterility. RESULTS The resulting MSC were negative for CD33, CD34 and HLA-DR but showed high expression of CD90, CD105 and HLA-ABC (average expressions of 94.3%, 75.8% and 94.2%, respectively). Chondrogenic, osteogenic and adipogenic differentiation potential was demonstrated. The MSC retained their ability to differentiate into osteogenic lineage when seeded onto collagen scaffolds after exposure to a clinical grade medium. Cell numbers and cell viability were adequate for clinical use, and microbiologic assays demonstrated the absence of any contamination. DISCUSSION In the specific context of a degenerative bone disease with limited involvement of skeletal tissue, the combined use of MSC, exposed to an osteogenic clinical grade medium, and biomimetic biodegradable scaffolds offers the possibility of producing adequate numbers of biologic tissue-engineered cell-based constructs for use in clinical trials.
Collapse
Affiliation(s)
- A Salvadè
- Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Li LH, Biagi E, Allen C, Shivakumar R, Weiss JM, Feller S, Yvon E, Fratantoni JC, Liu LN. Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells. Cancer Gene Ther 2006; 13:215-24. [PMID: 16082377 DOI: 10.1038/sj.cgt.7700883] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Interactions between CD40 and CD40 ligand (CD154) are essential in the regulation of both humoral and cellular immune responses. Forced expression of human CD154 in B chronic lymphocytic leukemia (B-CLL) cells can upregulate costimulatory and adhesion molecules and restore antigen-presenting capacity. Unfortunately, B-CLL cells are resistant to direct gene manipulation with most currently available gene transfer systems. In this report, we describe the use of a nonviral, clinical-grade, electroporation-based gene delivery system and a standard plasmid carrying CD154 cDNA, which achieved efficient (64+/-15%) and rapid (within 3 h) transfection of primary B-CLL cells. Consistent results were obtained from multiple human donors. Transfection of CD154 was functional in that it led to upregulated expression of CD80, CD86, ICAM-I and MHC class II (HLA-DR) on the B-CLL cells and induction of allogeneic immune responses in MLR assays. Furthermore, sustained transgene expression was demonstrated in long-term cryopreserved transfected cells. This simple and rapid gene delivery technology has been validated under the current Good Manufacturing Practice conditions, and multiple doses of CD154-expressing cells were prepared for CLL patients from one DNA transfection. Vaccination strategies using autologous tumor cells manipulated ex vivo for patients with B-CLL and perhaps with other hematopoietic malignancies could be practically implemented using this rapid and efficient nonviral gene delivery system.
Collapse
Affiliation(s)
- L H Li
- MaxCyte, Inc., Gaithersburg, Maryland, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
D'Amico G, Bonamino M, Dander E, Marin V, Basso G, Balduzzi A, Biagi E, Biondi A. T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia 2006; 20:2015-24. [PMID: 16990769 DOI: 10.1038/sj.leu.2404390] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Adoptive T-cell immunotherapy may provide complementary therapy for childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In this study, we have analyzed the functional characteristics of anti-BCP-ALL effector T cells generated by co-culturing T lymphocytes and dendritic cells (DC) from allogeneic human stem cell transplantation (HSCT) donors. After 21-day co-culture with DC pulsed with CD40L+ apoptotic BCP-ALL blasts, T cells presented with both effector and central memory phenotype, and showed high and specific cytotoxic activity against leukemic cells (average lysis = 77%), mostly mediated by CD8+ T cells. Noticeably, growth of CD4 T cells was maintained (45% of total cells), which actively produced Th1 cytokines (IFN-gamma, TNF-alpha, IL-2), but not IL-4, IL-5 and IL-10. Anti-BCP-ALL T cells expressed CD49d and CXCR4 (implicated in the recruitment to bone marrow), and CD62L and CCR7 (involved in the migration to lymphoid organs). In accordance with this profile, T cells significantly migrated in response to the chemokines CXCL12 and CCL19. In conclusion, stimulation of T cells with CD40L+BCP-ALL cells-loaded DC not only elicited the generation of potent and specific anti-leukemic cytotoxic effectors, but also the differentiation of specific and functional Th-1 CD4 lymphocytes. These effectors are fully equipped to reach leukemia-infiltrated tissues and have characteristics to support and orchestrate the anti-tumor immune-response.
Collapse
Affiliation(s)
- G D'Amico
- Centro Ricerca M. Tettamanti, Clinica Pediatrica Università Milano-Bicocca, Ospedale San Gerardo, Monza, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- E Biagi
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | |
Collapse
|
26
|
Todisco E, Gaipa G, Biagi E, Bonamino M, Gramigna R, Introna M, Biondi A. CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. Leukemia 2002; 16:2046-54. [PMID: 12357356 DOI: 10.1038/sj.leu.2402672] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2001] [Accepted: 05/30/2002] [Indexed: 11/09/2022]
Abstract
Childhood B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells, collected from bone marrow (BM) at diagnosis, were cultured, after thawing, on allogeneic human bone marrow stroma (HBMS) for 48 h in the presence of a soluble trimeric CD40 ligand (stCD40L) molecule. HBMS maintained leukemic cells viability in all tested cases (mean viability 85%). Under these culture conditions we noticed upregulation or de novo expression of costimulatory molecules CD40, CD80 (B7-1) and CD86 (B7-2) in 22/22, 15/23 and 21/23 cases, respectively. Upregulation, in terms of fluorescence intensity, was also observed in the expression of MHC I, MHC II, CD54 (ICAM 1) and CD58 (LFA 3) molecules. HBMS alone, although to a lesser extent, was able to induce modulation of these molecules, but not CD80, in a similar proportion of cases. Neither stCD40L nor HBMS induced modulation of CD10 and CD34 molecules. Moreover, in 4/4 tested cases, stCD40L-stimulated ALL cells were able to induce allogeneic T cells proliferation. To evaluate whether leukemia-reactive T cells were detectable in the BM of ALL patients at diagnosis, stCD40L-stimulated ALL cells were co-cultured with autologous T cells (ratio 1:1), isolated from BM at diagnosis, for 4 days and a 24 h ELISPOT assay was applied to detect the presence of interferon-gamma (IFN-gamma)-producing cells. In four of seven cases IFN-gamma-producing cells were detected with frequencies of 1/900, 1/1560, 1/2150 and 1/1575 autologous T cells. These data confirm that stCD40L exposure can activate the antigen-presenting cell (APC) capacity of BCP-ALL cells cultured on HBMS and that ELISPOT assay can be used to measure the frequency of leukemia-reactive autologous T cells in the BM of ALL patients even after short-term culture with stCD40L-stimulated ALL cells.
Collapse
Affiliation(s)
- E Todisco
- Centro Ricerca M Tettamanti, Clinica Pediatrica Università Milano-Bicocca, Ospedale San Gerardo, Monza, Italy
| | | | | | | | | | | | | |
Collapse
|
27
|
Biagi E, Breschi L, Granchi S, Masotti L. Comments on "Frequency decomposition and computing of ultrasound medical images with wavelet packets". IEEE Trans Med Imaging 2002; 21:834-837. [PMID: 12374321 DOI: 10.1109/tmi.2002.801177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
In this paper, errors and discrepancies in the subject paper [Cincotti et al., (2002)] are highlighted. A comment, concerning the axial resolution associated to the adopted processing procedure is also reported.
Collapse
|
28
|
Biagi E, Margheri F, Menichelli D. Efficient laser-ultrasound generation by using heavily absorbing films as targets. IEEE Trans Ultrason Ferroelectr Freq Control 2001; 48:1669-1680. [PMID: 11800130 DOI: 10.1109/58.971720] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
An efficient all-fiber optic source is presented; it adopts absorbing films, deposed directly over the fiber tip, as targets. It is demonstrated that the use of absorbing films made of pure graphite, or graphite powder mixed with epoxy resin, has produced a conversion efficiency increase of two orders of magnitude with respect to metallic materials. It is observed that the conversion efficiency increases monotonically as thickness is reduced down to the material optical penetration depth. Moreover, the conversion efficiency rises with the concentration of graphite powder. Principal advantages of this kind of source are the ease of production and miniaturization, the excellent electromagnetic compatibility, wide ultrasonic bandwidth and, consequently, high spatial resolution. The ultrasonic bandwidth can be controlled by varying the laser pulse duration. The possibility of generating ultrasonic signals with high frequency and flat spectral distribution makes the proposed device suitable for biological tissue spectral characterization.
Collapse
Affiliation(s)
- E Biagi
- Ultrasonic and Non-Destructive Testing Laboratory, Department of Electronics and Telecommunications, Florence, Italy.
| | | | | |
Collapse
|
29
|
Abstract
Intrathecal chemotherapy with antineoplastic agents is mainly utilised in children with leukaemia and lymphoma, and in selected brain tumours. In these diseases, intrathecal use is restricted to methotrexate (MTX), cytosine arabinoside (Ara-C) and corticosteroids. A number of other agents are, at the present time, under evaluation. Intrathecal MTX administered sequentially with systemic high dose MTX infusion prolongs therapeutic cerebral spinal fluid (CSF) levels of the drug. Prolonged therapeutic CSF levels can also be achieved by giving repeated small intrathecal doses of MTX over an extended period in selected patients, with an implanted Ommaya reservoir. In the CSF, the metabolic inactivation of Ara-C is significantly lower than in plasma with a CSF clearance similar to the rate of CSF bulk flow. A slow-release formulation of Ara-C may be given intrathecally, resulting in a prolonged cytotoxic concentration in the CSF. CNS relapse and neurotoxicity in patients with acute lymphoblastic leukaemia, especially younger children, may be reduced by using age-related dosing of intrathecal MTX and Ara-C. Hydrocortisone is used in combination with MTX and Ara-C for so-called 'triple intrathecal chemotherapy' in the treatment of meningeal leukaemia. Intrathecal thiotepa does not appear to be advantageous over systemic administration in patients with brain and meningeal leukaemia. Monoclonal antibodies, reactive with tumour-associated antigens, can be used as delivery systems for chemotherapeutic agents and radionuclides. However, the development of this new approach is currently under evaluation in larger clinical studies. Neurological adverse effects may be expected with intrathecal chemotherapy and are increased by high dose systemic therapy, concomitant cranial radiotherapy or meningeal infiltration by neoplastic cells. Inadvertant intrathecal administration of antineoplastic agents that are indicated for systemic administration only, is dangerous and may result in a fatal outcome.
Collapse
Affiliation(s)
- A Ruggiero
- Division of Paediatric Oncology, Catholic University, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
30
|
Bonanomi S, Balduzzi A, Tagliabue A, Biagi E, Rovelli A, Corti P, Crippa D, Uderzo C. Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease. Bone Marrow Transplant 2001; 28:631-2. [PMID: 11607781 DOI: 10.1038/sj.bmt.1703151] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2001] [Accepted: 07/05/2001] [Indexed: 11/08/2022]
|
31
|
Biagi E, Rovelli A, De Lorenzo P, Uderzo C. Autologous hematopoietic stem cell transplantation (AHSCT) as consolidation therapy for childhood acute myelogenous leukemia in 1st complete remission. Pediatr Hematol Oncol 2001; 18:359-62. [PMID: 11452409 DOI: 10.1080/088800101300312654] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Menichelli D, Biagi E. Optoacoustic sources: a practical Green function-based model for thin film laser-ultrasound generation. ACTA ACUST UNITED AC 2001. [DOI: 10.1088/1464-4258/3/4/355] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
33
|
Biagi E, Bambacioni F, Gaipa G, Casati C, Golay J, Biondi A, Introna M. Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells. Haematologica 2001; 86:13-6. [PMID: 11146564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Gene manipulation and cell vaccines represent innovative strategies to enhance the immunogenicity of cancer cells. We adopted a defective lentivirus derived from the human immunodeficiency virus (HIV)-1 backbone and carrying the enhanced green fluorescent protein (EGFP) gene to transduce primary human acute myelogenous leukemia (AML) and B-precursor acute lymphoblastic leukemia (ALL) cells. DESIGN AND METHODS AML blasts were maintained with or without cytokines (stem cell factor, FLT3 ligand and interleukin 3) for 48 hours, and successively infected with two spin infection cycles. ALL blasts were cultured on a murine S17 stromal cell line. RESULTS As regards AML cells, the efficiency of infection at 7 days varied from 8.4 to 37%. As confirmed by cell cycle analysis, cells were, in most of the cases, blocked in different phases of the cycle and did not proliferate during culture: the infection was therefore obtained in the absence of cell proliferation. In contrast, the maintenance of optimal cell viability was of fundamental importance for obtaining good infection levels. As regards ALL blasts, the percentages of infection after 3 days varied from 4.4 to 21%. INTERPRETATION AND CONCLUSIONS These preliminary data suggest that gene delivery into primary human AML and B-precursor ALL cells by an HIV-1 derived lentiviral vector could represent a strategy for engineering leukemic cells for use as cancer vaccines.
Collapse
Affiliation(s)
- E Biagi
- Centro M. Tettamanti, Clinica Pediatrica Università di Milano Bicocca, Ospedale San Gerardo, Monza, Italy
| | | | | | | | | | | | | |
Collapse
|
34
|
Biagi E, Rovelli A, Balduzzi A, De Lorenzo P, Tagliabue A, Uderzo C. TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission. Bone Marrow Transplant 2000; 26:1260-2. [PMID: 11149746 DOI: 10.1038/sj.bmt.1702714] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
35
|
Uderzo C, Biagi E, Rovelli A, Balduzzi A, Schirò R, Longoni D, Arrigo C, Nicolini B, Placa L, Da Prada A, Mascaretti L, Giltri G, Galimberti S, Valsecchi MG, Locasciulli A, Masera G. Bone marrow transplantation for childhood hematological disorders: a global pediatric approach in a twelve year single center experience. Pediatr Med Chir 2000; 21:157-63. [PMID: 10767974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
One hundred and 43 consecutive pediatric patients (June 1985-December 1996) with at least 18 months of follow-up, were considered: most of the patients (111/143, 77.6%) underwent allogeneic BMT. The median follow-up was 5.7 years. Overall survival and 5 years EFS were 48.6% and 46.9%, respectively. For patients who underwent allogeneic BMT from HLA-identical siblings, the 5 years EFS for ALL was 75% in 1st CR, 60.4% in 2nd CR, 22.3% in > 2nd CR and 86.7% for AML in 1st CR. The EFS for Allo-BMT in "good" and "poor" prognosis patients was 68.6% and 21.8%, respectively (p value = 0.001). Early mortality in Allo-BMT patients was 17.7% between 1985-1990 and 10.3% between 1991-1996. Early treatment-related organ complications occurred mostly in patients who underwent BMT from an unrelated or a mismatched family donor. Late toxicity was evaluated in 57 patients (median follow-up of 82 months): none of the patients complained of significant late cardiac or respiratory dysfunction. With regards to growth, 18/57 patients (31.6%) lost more than two height centile channels. Three cases of thyroid neoplasms were observed. Evaluation of psychosocial functioning, studied in 39 patients who had at least 2 years of follow-up in CR, did not reveal any evident quality of life impairment. The possibility of curing childhood hematological malignancies is based on a global pediatric and multidisciplinary approach. A continuous need to improve results in terms of EFS and quality of life suggests that further multicenter prospective studies should be carried out.
Collapse
Affiliation(s)
- C Uderzo
- Clinica Pediatrica, Ospedale San Gerardo di Monza, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Biagi E, Perseghin P, Buscemi F, Dassi M, Rovelli A, Balduzzi A. Effectiveness of extracorporeal photochemotherapy in treating refractory chronic graft-versus-host disease. Haematologica 2000; 85:329-30. [PMID: 10702832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
|
37
|
Biagi E, Assali G, Rossi F, Jankovic M, Nicolini B, Balduzzi A. A persistent severe autoimmune hemolytic anemia despite apparent direct antiglobulin test negativization. Haematologica 1999; 84:1043-5. [PMID: 10553166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Not all cases of autoimmune hemolytic anemia (AIHA) are diagnosed by the direct antiglobulin test (DAT). We present and discuss a simple method of enhancing the sensitivity of the standard DAT. DESIGN AND METHODS We report the case of a five-month-old child diagnosed with a severe IgG-mediated AIHA, characterized by quick DAT negativization despite clinical worsening. Warm AIHA with negative DAT, possibly due to a low affinity autoantibody, unresponsive to conventional therapy, was hypothesized. RESULTS The DAT resulted strongly positive with anti-IgG serum using a 4C saline for erythrocyte washing, to reduce the dissociation of the supposed low affinity autoantibody. Very intensive cytoreductive treatment was administered twice until clinical remission was obtained. INTERPRETATION AND CONCLUSIONS The clinical course of AIHA can be dissociated by the DAT. Since autoantibody-mediated hemolysis with negative DAT rarely occurs, once other causes of high reticulocyte count anemia have been ruled out, the DAT after ice-cold saline washing could be a useful and easy means of corroborating the diagnosis of AHIA, when traditional methods fail.
Collapse
Affiliation(s)
- E Biagi
- Pediatric Hematology Department, Università di Milano, Ospedale S. Gerardo, Monza, Italy
| | | | | | | | | | | |
Collapse
|
38
|
Uderzo C, Fraschini D, Balduzzi A, Galimberti S, Arrigo C, Biagi E, Pignanelli M, Nicolini B, Rovelli A. Long-term effects of bone marrow transplantation on dental status in children with leukaemia. Bone Marrow Transplant 1997; 20:865-9. [PMID: 9404928 DOI: 10.1038/sj.bmt.1700993] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Minimal data about oral and dental health in long-term survivors after BMT are available. We studied the dental status of 27 children (19 males, eight females) with leukaemia, followed up with a routine oral examination, panoramic tomogram and, when necessary, an endoral radiograph at a median of 2 years (range 1-10) after BMT. Community periodontal index treatment necessity (CPITN), dental caries, missing or filled permanent teeth (DMFT) and dento-facial alterations according to WHO criteria were registered and evaluated. Median age of the patients at BMT was 9 years (range 1.1-17.9). The mean DMFT score ranged from 1.6 to 12.4 according to age at examination and was slightly higher than that which we previously reported in children who received chemotherapy alone. CPITN showed the presence of soft deposits in 77.7%, serious gingivitis in 59.2% and parodontal involvement in 3.7% of cases. Dento-facial abnormalities were found in 55.5% of patients, while 62.9% of the patients had tooth abnormalities or agenesis. Nine out of 27 patients (33%) had root hypoplasia. A negative impact on DMFT index due to multiple post-BMT factors was found. Age is the crucial factor in determining a developmental defect of enamel and root. The follow-up of long-term survivors after BMT should include regular dental examination.
Collapse
Affiliation(s)
- C Uderzo
- Clinica Pediatrica dell'Università di Milano, Ospedale S Gerardo, Monza, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Dell'Orto M, Rovelli A, Barzaghi A, Valsecchi MG, Silvestri D, Giltri G, Balduzzi A, Biagi E, Arrigo C, Rossi MR, Masera G, Uderzo C. Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience. Pediatr Hematol Oncol 1997; 14:335-47. [PMID: 9211538 DOI: 10.3109/08880019709041593] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
One hundred fifty-six episodes of fever occurred in 102 children during the first 100 days after bone marrow transplantation (BMT) performed at a single institution: fever of undetermined origin (FUO), 40.3%; septicemia, 7.1%; pneumonia, 19.2%; other infections, 33.4% of cases. The overall incidence of mortality was 22.6% and of mortality due to infections 17.4%. All FUO episodes resolved. Pneumonia was the major cause of death; 60% of recipients who developed pneumonia died, accounting for 90% of deaths attributable to febrile complications. Interstitial pneumonia, occurred rarely, in 3.9% of all febrile episodes. The Cox model showed that the presence of graft-versus-host disease (GVHD) was related to an approximately ninefold increase in the risk of a first episode of FUO (P value .03). The risk of developing pneumonia was fourfold greater in children who received a transplant from a matched unrelated donor or a mismatched family donor (P value .01). Developments in diagnostic tools are needed to diagnose febrile episodes earlier and more precisely with the aim of reducing early mortality after BMT.
Collapse
Affiliation(s)
- M Dell'Orto
- Università di Milano, Ospedale San Gerardo, Monza, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Biagi E, Arrigo C, Dell'Orto MG, Balduzzi A, Pezzini C, Rovelli A, Masera G, Silvestri D, Uderzo C. Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies. Support Care Cancer 1997; 5:228-33. [PMID: 9176970 DOI: 10.1007/s005200050065] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The aim of this study was to compare the Hickman and Groshong central venous catheters (CVCs) for incidence and severity of catheter-related complications in children. Seventy-three patients with hematological malignancies were observed, 42 with Groshong CVCs and 31 with Hickman CVCs. The number of infective episodes per 100 CVC-days was not significantly different (0.25 in the Hickman group versus 0.13 in the Groshong group; P = 0.24). The most frequent type of CVC-related infection in both groups was microbiologically documented sepsis; in most cases Gram-positive bacteria were isolated. Neutropenia (P < 0.001 for both CVCs) and hospital CVC management (P = 0.0047 for the Hickman group, P < 0.001 for the Groshong group) emerged as the major risk factors for the outbreak of infections. The rate of mechanical complication episodes per 100 CVC-days was similar in both groups (1.01 in the Hickman group versus 1.1 in the Groshong group: P = 0.58). Some complications (fissures, ruptures, total lumen obstruction by clots) occurred only in the Groshong group. Our study did not demonstrate any statistically significant difference in the incidence of mechanical and infective CVC-related complications between these two types of catheter.
Collapse
Affiliation(s)
- E Biagi
- Clinica Pediatrica dell'Università di Milano, Ospedale San Gerardo, Monza, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Marchi P, Uderzo C, Riva A, Rovelli A, Biagi E, Arrigo C, Marraro G, Masera G. Role of early diagnosis for a noninvasive treatment of pulmonary thromboembolism in leukemic children. Support Care Cancer 1997; 5:417-20. [PMID: 9322356 PMCID: PMC7102284 DOI: 10.1007/s005200050102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Pulmonary thromboembolism (PTE) in leukemic children undergoing intensive chemotherapy should be promptly recognized so that specific therapy can be started. Our experience with the two cases reported here has led us to propose guidelines for the treatment of initial PTE in a pediatric hematology unit. Two children with leukemia developed PTE, the first during the relapse for acute lymphoblastic leukemia and the second at the onset of acute promyelocytic leukemia. In both cases, the diagnosis of PTE was based on clinical assessment of sudden acute respiratory failure with positive pulmonary perfusional scintigraphy in spite of a negative chest X-ray. The subintensive supervision consisted of instrumental monitoring with the assistance of an intensive care anesthetist. The clinical monitoring was based on the serial registration of respiratory rate, cardiac rate, SaO2 and body temperature. The thrombolytic therapy, together with heparin prophylaxis, was successfully administered in the hematology ward without the need for intensive care support (i.e. mechanical ventilation). The success of the treatment was documented by the criterion of a return to the normal cardiorespiratory parameters a few hours after the start of the thrombolytic treatment. Furthermore, a chest CT scan in case 1 and an arteriography in case 2 confirmed the PTE-related hypoperfusion. On the basis of this experience, the authors point out that in the course of acute respiratory failure in leukemic children, the combination of a negative chest X-ray and a positive pulmonary perfusional scintigraphy (compared whenever possible with ventilatory scintigraphy) in the presence of a negative CT scan could be a reliable diagnostic tool for PTE. This pathology should be treated promptly and with specific therapy to avoid progression to a severe, massive PTE.
Collapse
Affiliation(s)
- P Marchi
- Servizio di Anestesiologia, Ospedale San Gerardo, Monza, Italy
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Uderzo C, Valsecchi MG, Balduzzi A, Rovelli A, Dini G, Miniero R, Locatelli F, Rondelli R, Arcese W, Andolina M, Messina C, Polchi P, Biagi E, Arrigo C, Silvestri D, Masera G, Bacigalupo A. Treatment of childhood acute lymphoblastic leukemia in first remission with allogeneic bone marrow transplantation or with intensive chemotherapy: a cooperative Italian study. The AIEOP (Associazione Italiana Ematologia ed Oncologia Pediatrica) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy. Bone Marrow Transplant 1996; 18 Suppl 2:25-7. [PMID: 8932793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- C Uderzo
- Clinica Pediatrica, Ospedale San Gerardo, Monza, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Affiliation(s)
- R Maiorca
- Division of Nephrology, University of Brescia, Italy
| | | | | | | | | | | |
Collapse
|